+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Company Analysis: Incyte

The publisher explores Incyte’s prescription pharmaceutical performance and outlook over 2019-29.


  • Overview - Incyte continues to be driven by robust Jakafi sales.
  • Key themes - [1] Incyte continues to grow Jakafi volumes at a strong pace, with supplemental approvals and label expansions adding to the lifecycle management of the drug [2] Jakafi patent expiration in 2028 is a key event for Incyte as the drug will comprise a significant proportion of company revenues [3] Royalties and collaboration revenues will substantially bolster Incyte over the forecast period.

Model updates (6 November 2020)

  • Pemazyre forecast adjusted higher due to launch trend.

Model updates (4 August 2020)

  • Tafasitamab name changed to Monjuvi following US July approval
  • Itacitinib forecast pushed back due to treatment-naïve acute GVHD trial results
  • Jakafi forecast adjusted lower due to COVID-19 impact
  • Pemazyre 5EU and RoW forecast added due to pending EU approval decision.

Model updates (5 May 2020)

  • Jakafi forecast adjusted higher due to continued uptake in GVHD
  • Pemigatinib name changed to Pemazyre; forecast pulled forward due to earlier-than-anticipated approval for cholangiocarcinoma
  • Tafasitamab forecast added due to closing of licensing agreement with MorphoSys.

Model updates (13 February 2020)

  • Jakafi forecast adjusted higher due to continued growth in MF, strong growth in PV, and an above-expectations launch in steroid-refractory acute GVHD.

Table of Contents

Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison

Recent Earnings Review
  • Earnings Overview

Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis

Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights

Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug